featured
SGLT2 Inhibitors and the Risk of Ketoacidosis in Patients With Type 2 Diabetes
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Diabetes, Obesity & Metabolism
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Sodium-Glucose Co-Transporter-2 Inhibitors and the Risk of Ketoacidosis in Patients With Type 2 Diabetes Mellitus: A Nationwide Population-Based Cohort Study
Diabetes Obes Metab 2018 Mar 22;[EPub Ahead of Print], YG Kim, JY Jeon, SJ Han, DJ Kim, KW Lee, HJ KimFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.